Reuters logo
Bayer's Nexavar meets goal in thyroid cancer trial
January 3, 2013 / 7:51 AM / 5 years ago

Bayer's Nexavar meets goal in thyroid cancer trial

FRANKFURT, Jan 3 (Reuters) - German drugmaker Bayer said its drug Nexavar reached a goal of improving the survival of patients with a certain type of thyroid cancer in a late-stage trial.

It said on Thursday it plans to submit data from the trial as the basis for marketing approval of Nexavar to treat radioactive iodine refractory differentiated thyroid cancer. (Reporting by Maria Sheahan)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below